Novartis AG (NVS) NYSE

130.36

-1.28(-0.97%)

Updated at October 24 04:00PM

Currency In USD

Novartis AG

Address

Lichtstrasse 35

Basel, 4056

Switzerland

Phone

41 61 324 1111

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

75883

First IPO Date

November 07, 1996

Key Executives

NameTitlePayYear Born
Dr. Vasant Narasimhan M.D.Chief Executive Officer8.01M1976
Dr. Robert Kowalski Pharm.D.Chief People & Organization Officer2.3M1968
Dr. Steffen Lang Ph.D.President of Operations2.56M1967
Ms. Karen L. HaleChief Legal & Compliance Officer2.56M1968
Mr. Harry KirschChief Financial Officer3.97M1965
Dr. Patrick Horber M.D.President of International4.06M1970
Mr. Victor BultoPresident of US4.27M1978
Paul PenepentHead of Group Financial Reporting and Accounting0N/A
Ms. Sloan SimpsonGlobal Head of Investor Relations0N/A
Dr. Linda W. Armstrong M.D.Global Head of Respiratory Development01964

Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.